Related Experiment Videos

Fibrin monomer complexes (SFMC) after substitution of antithrombin III (AT III) in consumption coagulopathy

G Töpfer1, W Ehrhardt, G Dornheim

  • 1District Hospital of Görlitz, GDR.

Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1988
PubMed

Insights

Antithrombin III (AT III) donation effectively treated consumption coagulopathy in 33 patients. Monitoring AT III and soluble fibrin monomer complexes (SFMC) aids in detecting disseminated intravascular coagulation (DIC).

Area of Science:

  • Hematology
  • Coagulation Science

Background:

  • Consumption coagulopathy, including disseminated intravascular coagulation (DIC), presents complex challenges in patient management.
  • Substitution therapy is a critical aspect of treating severe coagulation disorders.

Observation:

  • This study investigated the effects of Antithrombin III (AT III) substitution therapy in 33 patients with consumption coagulopathy.
  • Key coagulation and fibrinolytic variables were monitored before and after treatment.

Findings:

  • Successful AT III donation led to the disappearance of soluble fibrin monomer complexes (SFMC) within 0.5-12 hours.
  • Decreased AT III levels correlated with a positive SFMC test, indicating recurrent DIC.
  • D-dimer proved a sensitive indicator for DIC during hyperfibrinolysis.
  • Fibronectin and SFMC levels showed an inverse relationship.

Implications:

  • Monitoring both AT III and SFMC is recommended for early detection of DIC.
  • D-dimer analysis is valuable for identifying DIC, especially in hyperfibrinolytic states.
  • Understanding the interplay between fibronectin and SFMC can refine diagnostic approaches for coagulation disorders.

Related Concept Videos